Treatment of Oxidative Stress With Chelation Therapy

Zarbin, Marco A.

doi:10.1001/jamaophthalmol.2013.1306

Search citation statements

Order By: Relevance

Paper Sections

Select...

Drugs Targeting Oxidative Stress1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[159][160][161][162] Chelating agents can be used to ameliorate the consequences of metal ion accumulation. [163][164][165][166] Neuroprotective effect obtained in animal models of ALS and a small Phase II clinical trial (NCT02164253) of deferiprone, a chelator of iron ions used for the treatment of thalassemia, 167,168 encouraged further assessment of this drug for the elimination of excess iron from the brain without changes in systemic iron levels in a larger Phase II clinical trial (NCT03293069).…”

Section: Drugs Targeting Oxidative Stressmentioning

confidence: 99%

In a search for efficient treatment for amyotrophic lateral sclerosis: Old drugs for new approaches

Kukharsky

Skvortsova

Бачурин

et al. 2020

Medicinal Research Reviews

View full text Add to dashboard Cite

Recent progress in understanding the pathological changes in the nervous system and in certain other body systems (e.g., immune system) that lead to the development and progression of amyotrophic lateral sclerosis (ALS) revealed a number of molecular and cellular processes that can potentially be used as therapeutic targets. Many of these processes are compromised not only in ALS but also in other diseases and a repertoire of drugs able to restore, at least partially, their functionality has been developed. In this review, we briefly describe current approaches to the repurposing of such "old" drugs for treatment of patients with ALS.

show abstract